Miscellaneous

Home / Resources / Posters Poster Improving Clinical Translation Through Human Skin-Based New Approach Methodologies Adeline Chaubet1, Mathias Peries1, Mamoudou Diallo1, Laurianne Kandalaft1, Anthony David1, Emeline Pagès1, Nicolas Gaudenzio1,2 1Genoskin SAS, Toulouse, France & 2University of Toulouse, Inserm, CNRS, Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Toulouse, France. Advancing drug development with New Approach Methodologies (NAMs) Accurate prediction ofRead more

Home / Resources / Posters Poster A drug development platform for immunogenicity and toxicity assessment using advanced multi-omic profiling Manon Scholaert1,2, Mathias Peries2, Emilie Braun2, Alexandra Ochando3, Emeline Pagès2 and Nicolas Gaudenzio1,2 1Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291 - CNRS UMR5051 - University Toulouse III, France, 2Genoskin SAS, Toulouse, France, 3Genoskin Inc, Salem MA, USA LongitudinalRead more

Home / Resources / Posters Poster Human primary mast cells as an advanced model for drug development Chenyan Wu1, Anthony David1, Anne Dalapa-Amana1, Catherine Marques1, Alexandra Ochando2, Lorna Santos2 and Nicolas Gaudenzio3 1Genoskin SAS, Toulouse, France, 2Genoskin Inc, Salem MA, USA, 3Toulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291 - CNRS UMR5051 - University Toulouse III, France ARead more

Conferences & eventsThank you for meeting our amazing teamGenoskin at the MPS World Summit 2026Enabling preclinical drug development with ex vivo human skin platforms Genoskin was proud to participate in the MPS World Summit 2026, held in Washington, DC, one of the leading global events dedicated to advancing microphysiological systems (MPS) and human-relevant models for drug development. The summit broughtRead more

Genoskin & argenx showcase human-based NAM platformPress release Published March 18, 2026 Genoskin presents translational human-based NAM platform at SOT 2026 in collaboration with argenxAt the 2026 annual meeting of the Society Of Toxicology (SOT), we will present new data demonstrating the value of our HypoSkin® ex vivo human skin platform as a translational human-based New Approach Methodology (NAM) forRead more

Conferences & eventsCome & meet our amazing teamGenoskin at The American Academy of Allergy, Asthma, & Immunology (AAAAI) Annual Meeting 2026Enabling non-clinical immune assessment through ex vivo human skin and mast cell models Genoskin was pleased to participate in the American Academy of Allergy, Asthma, & Immunology (AAAAI) Annual Meeting in Philadelphia, PA, one of the world’s leading scientific gatheringsRead more